Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

December 7, 2023

Voyager Therapeutics selects lead development candidate for SOD1 ALS gene therapy programme

Voyager Therapeutics has chosen a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) gene therapy programme.

Voyager Therapeutics selects lead development candidate for SOD1 ALS gene therapy programme